about
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.Pharmacogenomics and the treatment of acute myeloid leukemia.Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation.Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker.Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler.[Evaluation of the written informed consent form in clinical trials]Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature reviewPositive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysisDifferences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaUse of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patientsPilot evaluation of home delivery programme in haemophiliaPharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid LeukemiaBayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia ADaunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature reviewRoutine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patientsCross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate® ) and BAY 81-8973 (Kovaltry® ) in patients with severe or moderate haemophilia A in prophylaxisIDH1-mutated relapsed or refractory AML: current challenges and future prospectsDevelopment and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
P50
Q33441706-2778C579-AABA-4D2B-8900-7A6CF7D88C2AQ33442326-5D200F89-3E19-4530-A2C1-D8518C81FAFDQ33442358-A3D41E7E-D600-49B7-A9FD-A00AF7BBE195Q38307360-1C9FB593-34F1-42F9-842E-C5B2295B3534Q38661750-00D0E8B8-07E0-4CA4-B9FF-2935E4C85D64Q38887034-63588966-5287-4B88-B8E1-39CE5849B378Q39117010-529491F0-FFBF-46A3-A7EC-06E63D14D16AQ41142112-86B68876-F0EB-4328-9D94-D89FF1E4FEA8Q42149776-6B2D5DED-BBD0-44C4-90B1-BC02F91B2B97Q48357830-77262B49-79C1-40A2-BA5C-D974CF86602FQ52911206-7127C179-A86D-494E-BF0D-6F9E0951064FQ56772757-7560E35E-1CD8-4EAB-9DF4-75014E0DA857Q57177621-96AE422E-A7B8-4360-9E1A-4D6BE085D9ECQ63433257-5BAF6B54-EB17-48FF-9DD6-595E30CCE126Q64082218-30377404-8B1C-4625-A8D9-C3B59D07ACA0Q87641768-328D24E4-1600-4F8B-83D5-F9B28493F610Q89115067-643B9AE2-5E1E-451B-8040-39FB2E3311D2Q89792220-9C687930-FCAB-4035-86CA-131E3B2858CBQ91004452-A1AC1639-728B-4D76-866D-EA10AAAF3B0AQ91175679-CA9BB758-48DB-4D10-8296-0B7F32FA806FQ92210336-98E3B4CE-F574-48A3-9B27-FF1BAD5C33E5Q92331595-63B520D8-120F-4079-BDB2-00C19A9B38D7Q92626865-DF771E42-E24E-44A1-8759-F2957C5DD622Q92763917-620A3B62-FF8E-4E8C-AC6F-E5783EE362F4
P50
description
investigador
@es
researcher
@en
name
J E Megías-Vericat
@en
type
label
J E Megías-Vericat
@en
prefLabel
J E Megías-Vericat
@en
P31
P496
0000-0002-0369-5341